ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Bead-Based Quantum Dot Immunoassay Integrated with Multi-Module Microfluidics Enables Real-Time Multiplexed Detection of Blood Insulin and Glucagon.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MetaboSense: An Integrated Quantum Dot-Mediated Aptamer Assay and Modular Microfluidic Platform for Continuous In-Line Monitoring of Lung Metabolism During Ex Vivo Perfusion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evolution of Next-Generation Multiplex Lateral Flow Immunoassays: From Engineered Nanomaterials to AI-Driven Detection.Biosensors · 2026Review
- Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration.Bioengineering (Basel, Switzerland) · 2026Review
- A Bead-Based Quantum Dot Immunoassay Integrated with Multi-Module Microfluidics Enables Real-Time Multiplexed Detection of Blood Insulin and Glucagon.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Analyzing diabetes-related hormones such as insulin and glucagon using conventional enzyme-linked immunosorbent assay (ELISA) has been the gold standard. However, ELISAs have a long sample processing time, including blood serum/plasma preparation which restricts the number of measurement time points, making it difficult to accurately track hormone dynamics in relation to each other and to blood glucose levels. Here, a multi-module microfluidic platform, named quantum dot integrated real-time (QIRT)-ELISA system, that uses a bead-based quantum dot-mediated immunoassay (BQI) to continuously monitor insulin and glucagon in whole blood samples and in a multiplexed setting is demonstrated. The use of BQI simplifies the technical aspect of the system, removes the need for bulky and expensive equipment, and most importantly enhances the sensitivity, specificity, and temporal resolution. Validation experiments measuring levels of insulin and glucagon in rats during glucose tolerance tests demonstrate the accuracy of QIRT-ELISA for simultaneously measuring endogenous hormones within the physiological range during an oral glucose load.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.